FDA grants accelerated approval to sacituzumab govitecan-hziy (Trodelvy) for the treatment of metastatic urothelial cancer

Accelerated approval was based on data from the Phase 2, single-arm TROPHY study. Of the 112 patients who were evaluable for efficacy, 27.7% of those treated with sacituzumab responded to treatment, with 5.4% experiencing a complete response and 22.3% a partial response.

Source:

Biospace Inc.